Ph1 T-Regulatory Cells in Amyotrophic Lateral Sclerosis
| 대상 질환 | ALS |
|---|---|
| 임상 단계 | 1상 |
| 스폰서 | The Methodist Hospital Research Institute |
| 상태 | 완료 |
| 참여자 수 | 3 명 |
| 중재(약물) | Autologous T-regulatory lymphocytes, Interleukin-2 |
| 시작일 | 2016년 5월 16일 |
| 완료일 | 2018년 1월 5일 |
| 결과 공개일 | 2026년 6월 17일 |
요약
Open-label pilot study to determine the safety and tolerability of autologous CD4+ CD25+ regulatory T cells infusions with concomitant subcutaneous IL-2 injections taken 3 times per week in 3 participants with ALS.
Number of Participants With Treatment-related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE v4.0) & Medical Dictionary for Regulatory Activities (MedDRA).
| Treatment Arm | 0 Participants |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Ed — Shionogi
- Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic L — Shionogi
- Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) — Shionogi
- Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) — Shionogi
- Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis — Shionogi
- Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS — Shionogi